Royalty Pharma (RPRX) Loans and Notes Receivables (2019 - 2025)
Historic Loans and Notes Receivables for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $860.1 million.
- Royalty Pharma's Loans and Notes Receivables rose 1231.44% to $860.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $860.1 million, marking a year-over-year increase of 1231.44%. This contributed to the annual value of $783.8 million for FY2024, which is 613.89% up from last year.
- Latest data reveals that Royalty Pharma reported Loans and Notes Receivables of $860.1 million as of Q3 2025, which was up 1231.44% from $842.9 million recorded in Q2 2025.
- In the past 5 years, Royalty Pharma's Loans and Notes Receivables ranged from a high of $860.1 million in Q3 2025 and a low of $522.4 million during Q1 2021
- Moreover, its 5-year median value for Loans and Notes Receivables was $691.3 million (2022), whereas its average is $689.0 million.
- Per our database at Business Quant, Royalty Pharma's Loans and Notes Receivables soared by 1657.81% in 2022 and then soared by 276.58% in 2024.
- Over the past 5 years, Royalty Pharma's Loans and Notes Receivables (Quarter) stood at $614.4 million in 2021, then increased by 12.53% to $691.3 million in 2022, then rose by 6.82% to $738.4 million in 2023, then increased by 6.14% to $783.8 million in 2024, then increased by 9.74% to $860.1 million in 2025.
- Its Loans and Notes Receivables stands at $860.1 million for Q3 2025, versus $842.9 million for Q2 2025 and $716.6 million for Q1 2025.